Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | FOLH1 | Q04609 | 8/20 | 0.50 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.40 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.40 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5060110 | 0.84 | PTGS1 (0.52) | CYP2D6FOLH1 | |
| SCHEMBL5051320 | 0.82 | MME (0.52) | CYP2D6FOLH1MAPK1 | |
| SCHEMBL5057985 | 0.81 | MTNR1A (0.50) | FOLH1LMNA | |
| SCHEMBL5054430 | 0.80 | GRM8 (0.47) | LMNA | |
| SCHEMBL5051123 | 0.80 | SMN1; SMN2 (0.53) | FOLH1LMNAMAPK1 | |
| SCHEMBL5060121 | 0.79 | FOLH1 (0.50) | FOLH1GRM2GRM3 | |
| SCHEMBL5217064 | 0.79 | CYP2D6 (0.57) | CYP2D6SRCLMNAMAPK1 | |
| SCHEMBL5052925 | 0.78 | CYP2D6 (0.52) | CYP2D6SRCLMNAMAPK1 | |
| SCHEMBL2387431 | 0.74 | CYP2D6 (0.61) | CYP2D6SRCLMNAMAPK1 | |
| SCHEMBL20875949 | 0.74 | CYP2D6 (0.61) | CYP2D6GRM2GRM3SRCLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2002057222-A9 | THIOL-BASED NAALADASE INHIBITORS | GUILFORD PHARM INC (US) | 2004-05-06 | — | — | WO | claimed |
| US-20030216468-A1 | Thiol-based NAALADase inhibitors | GUILFORD PHARMACEUTICALS INC. | 2003-11-20 | — | — | US | claimed |
| EP-1353903-A2 | THIOL-BASED NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 2003-10-22 | — | — | EP | claimed |
| US-6586623-B2 | Carbocyclic mercaptans such as 3-carboxy-alpha-(3-mercapto-propyl) benzenepropanoic acid, used as N-acetylated alpha-linked acidic dipeptidase(NAALADase) inhibitors and for medical diadnosis | GUILFORD PHARMACEUTICALS INC. | 2003-07-01 | — | — | US | claimed |
| US-20030105088-A1 | Thiol-based NAALADase inhibitors | GUILFORD PHARMACEUTICALS INC. | 2003-06-05 | — | — | US | claimed |
| WO-2002057222-A2 | THIOL-BASED NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 2002-07-25 | — | — | WO | claimed |
| EP-2025666-A2 | Thiolalkyl benzoic acid derivatives | MGI GP, Inc. (US) | 2009-02-18 | — | — | EP | disclosed |
| EP-1406867-B1 | THIOLALKYL BENZOIC ACID DERIVATIVES | GUILFORD PHARM INC (US) | 2008-12-31 | — | — | EP | disclosed |
| US-20080311037-A1 | Compounds which bind PSMA and uses thereof | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2008-12-18 | — | — | US | disclosed |
| US-7220780-B2 | Naaladase inhibitors for treating retinal disorders and glaucoma | GUILFORD PHARMACEUTICALS INC. (US) | 2007-05-22 | — | — | US | disclosed |
| US-7138543-B2 | Thiolalkyl benzoic acid derivatives | GUILFORD PHARMACEUTICALS INC. (US) | 2006-11-21 | — | — | US | disclosed |
| WO-2006093991-A1 | COMPOUNDS WHICH BIND PSMA AND USES THEREOF | THE CLEVELAND CLINIC FOUNDATION (US) | 2006-09-08 | — | — | WO | disclosed |
| US-20060135812-A1 | Thiol-based NAALADase inhibitors | TSUKAMOTO TAKASHI | 2006-06-22 | — | — | US | disclosed |
| US-20030105088-A1 | Thiol-based NAALADase inhibitors | GUILFORD PHARMACEUTICALS INC. | 2003-06-05 | — | — | US | disclosed |
| US-20030100607-A1 | Mercaptoalkyl benzoic acid derivative are useful for inhibiting NAALADase (acetylated alpha-linked acidic dipeptidase/N-/) enzyme activity | EISAI INC. | 2003-05-29 | — | — | US | disclosed |
| EP-1292601-A2 | NAALADASE INHIBITORS FOR TREATING RETINAL DISORDERS AND GLAUCOMA | GUILFORD PHARMACEUTICALS INC. (US) | 2003-03-19 | — | — | EP | disclosed |
| US-20030036534-A1 | Naaladase inhibitors for treating retinal disorders and glaucoma | EISAI INC. | 2003-02-20 | — | — | US | disclosed |
| WO-2002096866-A2 | THIOLALKYL BENZOIC ACID DERIVATIVES | GUILFORD PHARMACEUTICALS INC. (US) | 2002-12-05 | — | — | WO | disclosed |
| WO-2002057222-A2 | THIOL-BASED NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 2002-07-25 | — | — | WO | disclosed |
| WO-2001092274-A2 | NAALADASE INHIBITORS FOR TREATING RETINAL DISORDERS AND GLAUCOMA | GUILFORD PHARMACEUTICALS INC. (US) | 2001-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135812-A1 | Thiol-based NAALADase inhibitors | NAALAD2, GLUL, GGCT | CYP2D6 3706/4885FOLH1 7/4885GRM2 510/4885 |
| US-20030100607-A1 | Mercaptoalkyl benzoic acid derivative are useful for inhibiting NAALADase (acetylated alpha-linked acidic dipeptidase/N-/) enzyme activity | NAALAD2, DNPEP, ALDH7A1 | CYP2D6 2981/4885FOLH1 14/4885GRM2 636/4885 |
| US-20030216468-A1 | Thiol-based NAALADase inhibitors | NAALAD2, GLUL, RIMKLA | CYP2D6 3474/4885FOLH1 6/4885GRM2 491/4885 |
| US-20080311037-A1 | Compounds which bind PSMA and uses thereof | FOLH1, PSMA1, BPHL | CYP2D6 2882/4885FOLH1 1/4885GRM2 3276/4885 |
| US-20030105088-A1 | Thiol-based NAALADase inhibitors | NAALAD2, GLUL, RIMKLA | CYP2D6 3474/4885FOLH1 6/4885GRM2 491/4885 |
| US-20030036534-A1 | Naaladase inhibitors for treating retinal disorders and glaucoma | ALDH1A2, GAA, PDE6A | CYP2D6 2755/4885FOLH1 124/4885GRM2 1377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.